MetaCap

PRF Technologies Ltd. (PRFX)

NASDAQ: PRFXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.4758-0.1476 (-23.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRFX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.09
52-week range
0.46 – 7.95
Day range
0.46 – 0.6005
Volume / Avg
69.82K / 228.55K
Beta
—

52-week range

$0.46$7.95

PRFX stock today

Shares of PRF Technologies (PRFX) finished lower on Nov 20 at $0.4758, a drop of 23.68% or $0.1476 per share, versus the S&P 500's 3.70% decline. Trading was light, with 69.82K shares changing hands, about 31% of the average daily volume. At this level, PRFX sits near the bottom of its 52-week range of $0.46 to $7.95: 94.0% below the high and 3.4% above the low.

PRF Technologies has posted a net loss over the last twelve months (EPS of -$4.09), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About PRF Technologies

Company profile

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Efraim Cohen-Arazi
Headquarters
Tel Aviv
Employees
6
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, PRF Technologies generated $17,000 in revenue, up 0.0% from fiscal 2024. PRF Technologies reported a net loss of $5.0 million, compared with a loss of $14.6 million a year earlier. Gross margin was -311.8% and operating margin -30129.4%.

PRF Technologies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$17.00K$0$0——
Growth—————
Net income$-5.02M$-14.59M$-9.34M$-8.79M$-7.25M
EPS (diluted)$-7.47$-105.52$-122.94$-63.46$-7.25

PRFX news

All PRFX news

PRF Technologies peers

Health Care sector
PRFX peer companies
CompanyPrice% ChgMarket capCompare
JUNSJupiter Neurosciences Inc.1.24-18.75%$1.63Mvs PRFX
KALAKALA BIO Inc.2.71-10.28%$1.74Mvs PRFX
SBFMSunshine Biopharma Inc.2.23-5.11%$1.84Mvs PRFX
PPBTPurple Biotech Ltd. ADR1.53-4.09%$1.86Mvs PRFX
PPCBPropanc Biopharma Inc.1.78+3.19%$1.87Mvs PRFX
XRTXXORTX Therapeutics Inc.0.839-5.73%$1.88Mvs PRFX
EOCNEocene Ltd.1.78+1.73%$1.90Mvs PRFX
APVOAptevo Therapeutics Inc.0.4041-2.37%$1.40Mvs PRFX

Indexes, lists and sector

PRF Technologies stock FAQ

What is PRF Technologies's stock price today?

PRFX last traded at $0.4758 as of Nov 20, 4:00 PM EST, down 23.68% on the day. Prices are delayed at least 15 minutes.

Who is PRF Technologies's CEO?

Mr. Efraim Cohen-Arazi is the chief executive officer of PRF Technologies Ltd., which has about 6 employees.

What is the PRFX 52-week high?

The 52-week high for PRFX is $7.95 and the 52-week low is $0.46. The stock is currently 94.0% below its high.

Compare PRFX